Erratum (DOI:10.1016/j.jacl.2008.01.002);Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising

Journal of Clinical Lipidology

Volumn 2, Issue 1, 2008, Pages 51-57

  Kon, Rachel H ^a   Russo, Mark W ^b   Ory, Bridget ^c   Mendys, Phil ^b   Simpson Jr , Ross J ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Direct to consumer advertising; Lipid management; Patient perceptions; Statins; Survey

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ACCURACY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CONSUMER; CONTROLLED STUDY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEAR; HEART INFARCTION; HUMAN; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE;

EID: 39349110068     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.04.001     Document Type: Erratum

References (22)

1. Top 200 brand-name drugs by units and by retail dollars in 2004. http://www.drugtopics.com/drugtopics/article/articleList.jsp?categoryId= 7604 Accessed April 19, 2005
2. Jawahar L., Mehta J.L., Bursac Z., Hauer-Jensen M., Fort C., and Fink L.M. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population. Am J Cardiol (2006) 923-928
3. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) by the National Cholesterol Education Program (NCEP). http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm Accessed August 8, 2006
4. Smith C.C., Bernstein L.I., Davis R.B., Rind D.M., and Shmerling R.H. Screening for statin-related toxicity. Arch Intern Med 163 (2003) 688-692
5. Russo M.W., and Jacobson I.M. How to use statins in patients with chronic liver disease. Cleve Clin J Med 71 (2004) 58-62
6. Tolman K.G. The liver and lovastatin. Am J Cardiol 89 (2002) 1374-1380
7. Cohen D.E., Anania F.A., and Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 97 suppl (2006) 77C-81C
8. Rosenthal M.B., Berndt E.R., Donohue J.M., Frank R.G., and Epstein A.M. Promotion of prescription drugs to consumers. N Engl J Med 346 (2002) 498-505
9. Lee W.M. Drug-induced hepatotoxicity. 349. N Engl J Med (2003) 474-485
10. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 1649-1657
11. Assy N., Kaita K., Mymin D., Levy C., Rosser B., and Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 45 (2000) 1929-1934
12. Chalasani N., Aljadhey H., Kesterson J., Murray M.D., and Hall S.D. Patients with elevated liver enzymes are not at risk for statin hepatotoxicity. 125. Gastroenterology (2004) 1287-1292
13. Morris L.S., and Schulz R.M. Patient compliance-an overview. J Clin Pharm Ther 51 (1992) 283-295
14. Dickinson D., and Theo Raynor D.K. What information do patients need about medicines?. BMJ 327 (2003) 861-864
15. Alm-Roijer C., Udén G., and Erhardt L. Better knowledge improves adherence to lifestyle changes and medication in patients with coronary heart disease. Eur J Cardiovasc Nurs 3 (2004) 321-330
16. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med (2006) 205-212
17. Penning-van Beest F.J., Termorshuizen F., Goettsch W.G., Klungel O.H., Kastelein J.J., and Herings R.M. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 28 (2007) 154-159
18. Kaiser Report #6084-Impact of direct-to-consumer advertising on prescription drug spending June 2003. Accessed August 20, 2006. www.kff.org
19. Clefee J.E., Winston C., and Stempski R. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. J Law Econ (2002) 673-690 XLV
20. Zachry III W.M., Dalen J.E., and Jackson T.M. Clinician's response to direct to consumer advertising of prescription medications. Arch Intern Med (2003) 1808-1812
21. Datti B., and Carter M.W. The effect of direct-to-consumer advertising on prescription drug use by older adults. Drugs Aging 23 (2006) 71-81
22. Broohhart M.A. Physician follow up and provider continuity are associated with long-term medication adherence. Arch Intern Med 167 (2007) 847-852